Rationale: Intrapleural therapy with a combination of tissue plasminogen activator (tPA) 10 mg and DNase 5 mg administered twice daily has been shown in randomized and open-label studies to successfully manage over 90% of patients with pleural infection without surgery. Potential bleeding risks associated with intrapleural tPA and its costs remain important concerns. The aim of the ongoing Alteplase Dose Assessment for Pleural infection Therapy (ADAPT) project is to investigate the efficacy and safety of dose de-escalation for intrapleural tPA. The first of several planned studies is presented here.
Pleural infection hospitalizes over 65,000 people in the United Kingdom and the United States each year, and its incidence continues to increase worldwide (1) (2) (3) (4) . Treatment involves evacuation of infected pleural fluid via chest tube drainage and antibiotics. However, conventional therapy fails in one in four patients, who require invasive surgery and/or die as a result of their illness (5) .
Treatment failure is frequently due to inadequate drainage of multiloculated effusions that develop as a consequence of fibrin deposition within the infected pleural space. Thus, intrapleural fibrinolytic therapy to lyse pleural loculations has attracted ongoing interest since 1949 (6) , with small studies (7, 8) demonstrating reductions in surgical intervention rates. Subsequently, the Multi-Centre Intrapleural Sepsis Trial (MIST)-1, the largest randomized controlled trial of an intrapleural fibrinolytic agent (streptokinase), failed to demonstrate any benefits over placebo for pleural infection. Similar results were found in the fibrinolytic-only (tissue plasminogen activator [tPA] ) arm of the MIST-2 trial (9, 10).
DNase was recently found to decrease the viscosity of infected pleural fluid (11) . Intrapleural therapy combining DNase and tPA facilitated pleural fluid drainage in animal studies (12) . In the MIST-2 study, 96% of patients who received intrapleural tPA 10 mg in combination with DNase 5 mg were successfully treated without needing surgery (9) . Similar success rates have been replicated in three open-label series (n = 107, n = 73, and n = 55 subjects) using the same combination doses (13) (14) (15) .
However, the potential bleeding risk associated with tPA remains the major concern of many clinicians in choosing between tPA/DNase therapy and surgical drainage. tPA also accounts for about 75% of the combined cost of tPA (10 mg) and DNase (5 mg) therapy in the United States, United Kingdom, and Australia.
tPA activates circulating plasminogen and the fibrinolytic cascade. When used for ischemic stroke, intravenous administration of tPA (0.9 mg/kg; maximum, 90 mg) is associated with significant risks of symptomatic intracranial hemorrhage (6.4% vs. 0.6% with placebo) (16, 17) . Intrapleural administration of tPA (with or without DNase) at 10 mg doses rarely causes systemic hemorrhage, but pleural bleeding has been reported at rates between 1.8 and 12% (13) (14) (15) 18) .
Bleeding risks are dose dependent when tPA is administered intravenously. A recent small study suggested the same may apply to intrapleural tPA use. The researchers in that study randomized patients to intrapleural treatment with 20 mg of tPA or urokinase, and the study was unblinded following serious pleural bleeds in five tPA-treated patients (28%) (18) . The pleural bleeding rate decreased to 12% when the study continued with tPA at 10 mg.
The dosing regimen of tPA 10 mg and DNase 5 mg administered intrapleurally twice daily, used in MIST-2, has since been widely adopted (9, 13, 14) . Interestingly, these drug doses were chosen empirically rather than being determined on the basis of conventional phase I dose escalation studies. Given the high clinical success rate with the tPA 10 mg/DNase 5 mg regimen, we hypothesized that lower doses of tPA (with DNase) could still provide similar treatment efficacy and might improve safety and reduce drug costs
The aim of the ongoing Alteplase Dose Assessment for Pleural infection Therapy (ADAPT) project is to investigate the efficacy and safety of dose de-escalation for intrapleural tPA instillation. In this first of several planned studies, we report patient outcomes from participating centers which adopted a reduced starting dose regimen of 5 mg tPA administered intrapleurally twice daily in combination with 5 mg of DNase for pleural infection. Partial results of this study were presented at the American Thoracic Society 2016 International Conference (19) .
Methods
Data were collected from Sir Charles Gairdner Hospital, Perth, Australia (September 2014-June 2016); North Bristol NHS Trust, Bristol, United Kingdom (March 2015-April 2016); Queen Elizabeth University Hospital, Glasgow, United Kingdom (February-April 2016); and Wellington Regional Hospital, Wellington, New Zealand (January-April 2016). The listed centers all employed tPA at 5 mg (with DNase 5 mg) during the study period as the standard starting dose as part of their local protocols, which allowed dose escalation of tPA at the discretion of the attending physician. Data were extracted retrospectively from case notes and hospital databases.
All patients in this study were treated according to usual local practice and assessed daily for clinical improvement. The suitability and timing of tPA/DNase therapy and other management decisions were determined by patients' attending physicians. All patients who were prescribed intrapleural tPA/DNase at each center during the study period received a starting dose of 5 mg of tPA with 5 mg of DNase. Decisions regarding dose escalation of tPA or surgical intervention were made by the treating physicians and were recorded. The study was approved by the institutional review board of Sir Charles Gairdner Group Human Research Committee. The ethics committees of the remaining participating centers (the NHS North Bristol Central and NHS Greater Glasgow and Clyde regional ethics committees and the New Zealand Health and Disability Ethics Committee) provided exemption for the project because it qualified as a retrospective audit and was exempted from formal approval.
Pleural infection was defined as in previous studies (9, 13) . All patients had clinical presentations consistent with pleural infection and pleural fluid that fulfilled at least one of the following characteristics: purulent fluid, pH less than or equal to 7.20, glucose less than or equal to 3 mmol/L (<55 mg/dl), and presence of microorganism(s) on Gram stain and/or bacterial culture.
Both tPA (5 mg) and DNase (5 mg) were diluted with 0.9% sodium chloride to 50 ml and administered twice daily. The duration of treatment was determined by the attending physicians on the basis of clinical response to treatment. In three centers, tPA (Actilyse; Boehringer Ingelheim, Ingelheim am Rhein, Germany) was instilled intrapleurally via a chest tube, which was then clamped for 40-60 minutes and then unclamped to allow 
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fluid drainage for 40-60 minutes. The process was then repeated with DNase 5 mg (Pulmozyme; Roche, San Francisco, CA). In one center (n = 5), both medications were instilled directly after each other before the tube was clamped.
The medical records were interrogated for patient demographics, comorbidities, and major life-limiting illness (defined as advanced cancer, end-stage renal/liver disease, severe chronic obstructive pulmonary disease, and heart failure), clinical observations, treatment and outcomes, surgical interventions, complications, and pleural fluid volume drained. The results of laboratory examinations, especially inflammatory markers, pleural fluid biochemistry, and microbiologic cultures, were recorded.
Data were collected during hospital admission and from routine outpatient clinic follow-up for 90 days. Chest radiographs (CXRs) were assessed for the area of pleural opacity occupied by the pleural effusion by one pulmonologist or radiologist using a validated method (9) . The CXR immediately prior to tPA/DNase treatment was compared with the first CXR available at a minimum of 72 hours following the first dose of tPA/DNase and with the CXR obtained at the completion of antibiotic therapy. Where a CXR was not available at the completion of antibiotic therapy, a CXR within 30 days after completion of the antibiotic course or the last available CXR during treatment was assessed.
Outcomes
The following outcomes were included: 
Statistical Analysis
Statistical analyses were performed using SigmaPlot 12.5 software (Systat Software, San Jose, CA). Results are presented as mean (SD) or median (interquartile range [IQR] ) based on the normality of the data. The Wilcoxon signed-rank test and paired t test (for nonparametric and parametric data, respectively) were used. Multiple-group comparisons were performed using analysis of variance on ranks, followed by Dunn's post hoc test. Significance was defined as P , 0.05.
Results
A total of 61 patients (41 males) with a mean age of 57 (SD 16) years were included from Sir Charles Gairdner Hospital (n = 36), North Bristol NHS Trust (n = 16), Queen Elizabeth University Hospital (n = 5), and Wellington Hospital (n = 4). Forty-two patients (69%) had one or more comorbidities. Of these patients, 28% had a major life-limiting illness ( Table 1 ).
The median (IQR) number of days from hospital admission to chest tube insertion was 2 (1-5) days. Most (n = 57 [93%]) patients received tPA/DNase therapy more than 24 hours following chest tube insertion, among whom 39% (n = 24) started therapy at least 48 hours after tube insertion. The majority of patients (n = 36 [59.0%]) were treated with 12-French chest tubes, followed by 18-French (n = 10 [16.4%]) and 32-French (n = 4 [6.5%]) drains. In two cases, the drain size was not recorded. Eight patients (13.1%) had an indwelling pleural catheter (IPC) in situ prior to diagnosis with pleural infection, seven for malignant pleural effusion and one for refractory pleural effusion resulting from congestive heart failure. Eight (13.1%) patients, including three with IPCs, had additional chest drains inserted for drainage.
All patients met the criteria for pleural infection ( Table 2 ). The mean CRP in the 24 hours preceding treatment was 225 mg/L (SD 105), and 51% of patients were febrile during this same period. In 37% of patients, the pleural fluid contained pus and/or yielded a positive bacterial culture. Follow-up data obtained at 90 days were available in 89.3% (n = 50) of these patients and confirmed resolution of pleural infection with all patients (100%) alive without requiring surgical intervention. The six (10.7%) remaining patients had a median follow-up of 52 (IQR, 35-59) days, at which time all were alive and did not require surgery.
Patients received a median of six (IQR, 4-6) doses of intrapleural tPA/DNase. Clinical resolution resulting in early treatment discontinuation occurred in 36% of patients who required a median of three doses (IQR, 2-4). Less than 5% (n = 3) of patients in the study received more than 6 doses, two of whom received 7 doses and one of whom received 12 doses. Seven patients (11.5%), including five patients with an IPC, had their tPA dose escalated to 10 mg during their treatment course, on average after 3.3 doses.
The median LOS was 7 (IQR, 5-10) days for the entire cohort and for those successfully treated. The LOS was 8 (IQR, 6-11.5) days for those who required dose escalation to 10 mg of tPA and 12 (IQR, 11.5-13) days for those who needed surgery.
Three
An 87-year-old subject died following admission with severe pneumonia and a heavily loculated parapneumonic effusion. He received six doses of tPA 5 mg/DNase 5 mg with significant improvements on the basis of CXR and CRP levels. However, he had multiorgan failure and was palliated because of his frailty, comorbidities, and finding of a necrotic subcarinal mass raising suspicion of cancer.
Radiology
Significant radiological improvements were observed with tPA/DNase treatment ( Figure 1 ). The percentage of hemithorax occupied by pleural opacity was reduced from a median of 42% (IQR, 22-58) seen on baseline CXR to 16% (IQR, 8-31) after at least 72 hours (P , 0.001). The pleural opacity was reduced to 5.0% of the hemithorax (IQR, 0.5-14.4) at Day 30 (IQR, 20-45) after treatment initiation in the 54 (96%) patients for whom CXR was available. This value was further reduced to 3.8% (IQR, 0.1-11.0) when patients with an IPC in situ at presentation were excluded from the analysis.
Volume of Pleural Fluid Drained
The median (IQR) volume of pleural fluid drained in the 24 hours preceding treatment was 175 ml (75-450), which increased to 1,157 ml (844-1,756) in the first 24 hours of tPA/DNase treatment and 2,025 ml (1,247-2,984) at 72 hours (P , 0.05) (Figure 2 ).
CRP
The median blood CRP at baseline was 220 mg/L (IQR, 140-301) and decreased by ORIGINAL RESEARCH 11% (IQR, 0 to 224) on Day 1 of tPA/DNase treatment ( Figure 3 ). However, in 30% (n = 16 of 53) of patients, the CRP remained greater than baseline at 48 hours. By Day 4 of treatment, a median reduction in CRP of 45% from baseline was observed (95% confidence interval, 37.9-56.8; P , 0.05). By Day 28 (IQR, 15-40), the CRP had reduced to 9.4 mg/L (IQR, 3-25).
Adverse Events
No systemic bleeding was reported for any patient. Three patients (4.9%) received blood transfusions; all were hemodynamically stable. Two had steadily decreasing blood hematocrit/hemoglobin levels, presumably resulting from drainage of large quantities of hemorrhagic pleural fluid, which triggered a clinical decision for blood transfusion.
The first patient drained 6,000 ml of heavily blood-stained fluid. Her hemoglobin dropped from 107 g/L to 73 g/L over 4 days, and she was transfused 2 U of packed red cells. She made an otherwise uneventful recovery.
The second patient had a long history of thrombocytopenia and was considered a high-risk candidate for surgery. She developed a hematoma at the chest tube insertion site that required a blood transfusion. She had ongoing infection. It was considered that tPA/DNase therapy posed lower risks than surgery, and she received six doses of tPA/DNase, which successfully treated the pleural infection. Her hemoglobin level gradually decreased (92 g/L to 72 g/L over 7 d) without hemodynamic compromise. She received a total of 5 U of packed red cells.
The third patient drained 2,575 ml of hemorrhagic fluid after the first three doses of tPA/DNase. Following the fourth dose, 400 ml of dark, venous-looking blood was drained. The fluid had a hematocrit (0.36) similar to that of corresponding serum. Treatment was ceased, and the blood loss stopped quickly thereafter. This patient received 1 U of packed red cells at the time as a preventive measure. He remained well and did not have any recorded drop in serum hemoglobin. He was discharged home 5 days after the start of tPA/DNase therapy.
Chest pain following tPA/DNase administration was common (36%) and responded to short-term escalation of analgesia or in frequency of opioid therapy in all patients. No patients ceased treatment as a result.
Discussion
Our data suggest that the efficacy and safety profile for intrapleural tPA at a starting dose of 5 mg (with 5 mg of DNase) is comparable to that achieved previously using higher doses of tPA for the treatment of pleural infection (Table 4) . Most patients (93.4%) in the present study were successfully treated and avoided surgery for pleural infection. The clinical success was corroborated by significant improvements in radiographic clearance, pleural fluid drainage, and a blood inflammatory marker. Treatment with a reduced tPA dose was well tolerated, and the incidence of blood transfusions (,5% of patients) was comparable to that in previous studies using 10 mg of tPA. Pleural blood loss was gradual, and no patients developed hemodynamic instability.
Pleural infection has a reported mortality of up to 20% (5). In the two largest randomized trials of pleural infection (9, 10), conventional treatment (systemic antibiotics and chest tube drainage) failed in 25 to 30% of the patients in the control groups, who required surgery. This contrasts with the results derived from tPA/DNase therapy, which cured over 90% of patients without surgery and produced significantly better radiographic clearance and shorter LOS than conventional treatment. Although intrapleural tPA/DNase therapy has attracted strong interest worldwide, hesitation in its implementation exists in many centers, particularly over concerns regarding bleeding risks and drug costs.
Doses of tPA used for intrapleural therapy range from 2 mg to 100 mg daily in published literature (20) . A study in horses (n = 25) that received treatment with intrapleural tPA for fibrinous pleuropneumonia demonstrated successful treatment with doses ranging from 0.375 mg to 20 mg of tPA, despite typically weighing in excess of 400 kg (21) . In the MIST-2 protocol, tPA was administered at 10 mg and DNase at 5 mg, twice daily for six doses. These doses were chosen empirically without support from prior dose escalation studies. The pharmacokinetics of tPA following intrapleural delivery is unknown; likewise, the optimal amount of tPA required to lyse fibrinous loculations remains unclear.
Using a lower starting dose of intrapleural tPA has a number of potential 
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advantages. The bleeding risks with tPA have been shown to be dose dependent following systemic administration; however, this is only causally linked following intrapleural administration. Although the rate of intrapleural bleeding in our study was similar to studies of 10 mg of tPA, there remains a theoretical potential to reduce adverse events with lower doses in stronger-powered studies. We have demonstrated treatment success, as measured by survival at discharge and avoidance of surgery at 30 days, similar to that of other pragmatic studies using 10 mg of intrapleural tPA (with 5 mg of DNase) (13) (14) (15) . Finally, this reduceddose regimen should reduce total drug costs.
The aim of the ADAPT project is to conduct stepwise dose de-escalation studies to establish the lowest effective dose for intrapleural tPA use in pleural infection.
This first ADAPT study confirmed our hypothesis that a lower (5 mg) starting dose of tPA provided treatment efficacy highly comparable to that of studies using higher tPA doses (Table 4) . ADAPT-2 is underway to establish the efficacy of tPA 2.5 mg/DNase 5 mg as a starting regimen. Others have investigated alternatives to the tPA/DNase protocol (e.g., daily dosing, instilling both drugs simultaneously, use of other fibrinolytics) (14, 15) .
Although not a direct comparison study, our patients and their disease severity were similar to those in prior studies. Most of our patients had major comorbidity and had complex pleural collections that failed to improve after the initial 24 hours of drainage. Indeed, 93% had multiloculated effusions visualized by ultrasonography. The patients were recruited consecutively to minimize selection biases. The magnitude of the volume of fluid drained over 72 hours, the rate of radiographic clearance, and the reduction in CRP in our study were highly comparable with open-label series using tPA 10 mg/DNase 5 mg (13) .
In total, 89% of patients were successfully treated with tPA (5 mg) without requiring dose escalation, thus justifying using 5 mg as a starting dose. Only in seven cases of our study did the clinicians raise the tPA dose to 10 mg, and these patients did not appear disadvantaged in their LOS and other outcomes.
Bleeding has long been a concern with intrapleural fibrinolytic use. The growing clinical experiences suggest that tPA very seldom induces pleural "hemorrhage" (i.e., massive rapid bleeding causing hemodynamic compromise). Instead, intrapleural fibrinolytics (e.g., tPA), via a monocyte chemotactic protein 
1-mediated mechanism (22) , stimulate production of large quantities (median, 1.5-2.6 L in published series) of hemorrhagic pleural fluid. Patients, especially those with significant comorbidity, may not be able to mount a hematopoietic response to compensate for the loss of red cells, resulting in a gradual decline in hematocrit (22) . 
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The present study has several limitations. The retrospective nature of our study prohibits direct comparison with the conventional 10 mg tPA dose or with patients treated for pleural infection who were not administered tPA/DNase therapy.
Comparison studies with 10 mg of tPA are required once the lowest effective dose of tPA is established through dose de-escalation studies. Second, like most other studies on this subject, there were no standard criteria for defining in which patients tPA/DNase therapy failed and who required surgery. As a pragmatic study, these decisions were left to the attending physician. It is well known that local practice and protocols differ around the world on the threshold of referring patients for surgery. Nonetheless, the vast majority of our patients did not require surgery, and their LOS was comparable to that reported in surgical series. It is therefore unlikely that they were subjected to an unusually high threshold for proceeding to surgery.
Third, eight patients had IPC-related pleural infections. These patients often have better outcomes than patients with non-IPCrelated pleural infection (23); however, they were included in the analysis to avoid selection bias. The small number of patients within our cohort is unlikely to alter our conclusion, but instead helps to inform the safety profile of the regimen. Last, the centers involved had all developed significant experience in the use of tPA/DNase and in pleural infection in general. It is difficult to determine if centers at the early learning phase can reproduce the same success rates.
Conclusions
The treatment success for patients who received a reduced starting dose of intrapleural tPA (5 mg) and DNase (5 mg) for pleural infection was 93%, with only 11% of patients requiring dose escalation to 10 mg of tPA. These observational data provide evidence that a starting dose of 5 mg tPA (with 5 mg DNase) intrapleurally for pleural infection is safe and effective. The findings of this observational, hypothesis-generating study need to be evaluated prospectively in future randomized clinical trials against higher published dose regimens. n Author disclosures are available with the text of this article at www.atsjournals.org.
